Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
By Saad Sayeed, Ariba Shahid and Steve Holland ISLAMABAD/WASHINGTON, April 25 (Reuters) - Iranian Foreign Minister Abbas Araqchi laid out...
It took less than three minutes for wind-whipped flames to go from licking the side of the house to shattering a window...
Investing.com – Morocco stocks were lower after the close on Thursday, as losses in the , and sectors led shares...
This article was written byFollowJR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and...
The Map is not the Terrain… https://theideafarm.com/markets/emerging-markets-the-map-is-not-the-terrain/ And also from a recent podcast with La Roche here is Gundlach “”My...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
